Concepedia

Publication | Open Access

Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis

DOIFull Paper Access

10

Citations

0

References

2008

Year

H M Albers, J.M.C. Wessels, RJH van der Straaten, D. M. C. Brinkman, L. W. A. van Suijlekom‐Smit, S. S. M. Kamphuis, HJ Girschick, Carine Wouters, MW Schilham, Saskia le Cessie,
Pediatric Rheumatology

Abstract

Methotrexate (MTX) is the most commonly used disease modifying antirheumatic drug (DMARD) in juvenile idiopathic arthritis (JIA), especially in polyarticular arthritis. At present no reliable prediction of individual response to MTX can be made. Identification of factors that influence the response to MTX could be helpful in realizing the optimal treatment for each individual patient.